Atlas Trials

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Clinical trial NCT03076437 · COMPLETED

Trial details

NCT number
NCT03076437
Sponsor
Shenzhen Institute for Innovation and Translational Medicine
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaLymphoma
Start date
2016-01-15
Primary completion
2019-05-26
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.